688302.SHG Hinova Pharmaceuticals Inc. A
- Market cap
- CNY 3.28B
- P/E
- -
- P/B
- 2.92x
- ROE
- -11.2%
- Dividend yield
- 0.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688302.SHG undervalued?
Graham numberThe Graham number of Hinova Pharmaceuticals Inc. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hinova Pharmaceuticals Inc. A fundamental analysis
No fundamental analysis for Hinova Pharmaceuticals Inc. A yet.
Hinova Pharmaceuticals Inc. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug…
Full company profileHinova Pharmaceuticals Inc. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hinova Pharmaceuticals Inc. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 4.23M | 0.00 | 0.00 | 1.65M | 0.00 | 367K | 20.5M | 110M |
| Gross Profit | 3.96M | 0.00 | 0.00 | 884K | 0.00 | 30.9K | 20.2M | 107M |
| Operating Income | -112M | -481M | -327M | -338M | -331M | -223M | -157M | -121M |
| EBITDA | -111M | -489M | -303M | -292M | -286M | -193M | -130M | -112M |
| Net Income | -112M | -490M | -306M | -302M | -294M | -199M | -137M | -112M |
| EPS | -1.50 | -6.60 | -3.09 | -3.05 | -2.97 | -2.01 | -1.39 | -1.14 |
| Balance Sheet | ||||||||
| Total Assets | 44.7M | 1.19B | 982M | 1.74B | 1.49B | 1.36B | 1.31B | 1.27B |
| Total Liabilities | 80.5M | 202M | 194M | 150M | 124M | 169M | 246M | 266M |
| Shareholders' Equity | -36.2M | 986M | 789M | 1.59B | 1.37B | 1.19B | 1.06B | 1.01B |
| Cash & Short-term Investments | 19.7M | 1.14B | 901M | 1.20B | 813M | 633M | 438M | 314M |
| Cash Flow | ||||||||
| Operating Cash Flow | -81.4M | -244M | -228M | -315M | -256M | -187M | -109M | - |
| Capital Expenditure | 1.13M | 2.50M | 19.8M | 69.2M | 99.2M | 89.5M | 82.9M | 29.3M |
| Free Cash Flow | -82.6M | -246M | -248M | -384M | -355M | -277M | -192M | -122M |
| Ratios | ||||||||
| ROE | - | -49.7% | -38.8% | -19.0% | -21.5% | -16.7% | -12.9% | -11.2% |
| ROA | -249.8% | -41.2% | -31.2% | -17.4% | -19.7% | -14.7% | -10.5% | -8.8% |
| Net Profit Margin | -2,642.9% | - | - | -18,264.5% | - | -54,382.8% | -670.5% | -102.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hinova Pharmaceuticals Inc. A dividends
- Dividend yield
- 0.04%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.24M | 0.01 | - |
| 2024 | - | - | - |
| 2023 | CNY 904K | 0.01 | - |
| 2022 | CNY 3.92M | 0.04 | - |
| 2021 | CNY 2.56M | 0.03 | - |
| 2020 | CNY 361K | 0.00 | - |
| 2019 | CNY 393K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hinova Pharmaceuticals Inc. A
- Insiders 30.30%
- Institutions 8.90%
- Public & others 60.81%
- Shares outstanding 99.0M
- Free float 71.4M
Hinova Pharmaceuticals Inc. A company profile
- Company name
- Hinova Pharmaceuticals Inc. A
- Ticker
- 688302.SHG
- ISIN
- CNE1000059F5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 241
- Fiscal year end
- December
- Address
- Building 1, Rongyao Building, Chengdu, China, 610041
- Phone
- 86 28 8505 8465
- Website
- hinovapharma.com
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops and produces therapeutics for cancers and metabolic syndromes. Its core product is Hainaan, a deuterium enzalutamide soft capsules for the treatment of prostate cancer; it also develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HP518, a PROTAC molecule targeting advanced prostate cancer; HP537, a small-molecule anti-tumor drug; HP515, an orally administered which improves liver and blood biochemical indicators; HP570, an orally administered molecular gel degrader targeting VAV1; and HC-X049, a small molecule project with STAT6 target layout. Hinova Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Chengdu, China.
Hinova Pharmaceuticals Inc. A management
9- Dr. Yuanwei Chen Ph.D.Chairman of the Board & General Manager · born 1963
- Mr. Xinghai Li M.D., Ph.D.Co-Founder & CTO · born 1963
- Ms. Li DaiVP of Operations, Secretary & Director · born 1981
- Ms. Ze Yan ShiFinancial Director · born 1981
- Jun HuAccounting Supervisor
- Tango TangVice President of Marketing
- Mr. Lei FanSenior Vice President of Pharmaceutical Chemistry · born 1976
- Mr. Wu DuSenior Vice President of Pharmaceutical Chemistry · born 1972
- Mr. Tong Tao KuangVice President of CMC · born 1981